Remission · adults (aged 18 years+) with depression in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depression rating scale scores ‐ not reported · adults (aged 18 years+) with depression in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acceptability ‐ total dropouts · adults (aged 18 years+) with depression in bipolar disorder
It is very uncertain whether riluzole changes acceptability: total dropouts compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults (aged 18 years+) with depression in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acceptability ‐ total dropouts · adults (aged 18 years+) with depression in bipolar disorder
It is very uncertain whether ketamine changes acceptability: total dropouts compared with placebo (very low certainty).
1 finding from 1 review
Acceptability ‐ dropouts due to adverse effects · adults (aged 18 years+) with depression in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Efficacy: number of participants who respond to treatment ‐ at 24 hours · adults with Major Depressive Disorder
It is very uncertain whether ketamine changes efficacy: number of participants who respond to treatment ‐ at 24… compared with placebo (very low certainty).
1 finding from 1 review
OR 3.94 [1.54, 10.1]
Studies not reported
Very low
Efficacy: number of participants who respond to treatment ‐ at 24 hours · adults with Major Depressive Disorder
Esketamine may leads to higher efficacy: number of participants who respond to treatment ‐ at 24… compared with placebo (low certainty).
1 finding from 1 review
OR 2.11 [1.2, 3.68]
Studies not reported
Low
Remission · adults with Major Depressive Disorder
Esketamine probably leads to higher efficacy: number of participants who achieve remission ‐ at 24 hours… compared with placebo (moderate certainty).
1 finding from 1 review
OR 2.74 [1.71, 4.4]
Studies not reported
Moderate
Depressive symptoms · adults with Major Depressive Disorder
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Acceptability ‐ total dropouts · adults with Major Depressive Disorder
Esketamine showed no clear difference in acceptability: total dropouts№ of participants: 773(5 RCTs) compared with placebo (moderate certainty).
1 finding from 1 review
OR 1.58 [0.92, 2.73]
Studies not reported
Moderate
Withdrawals due to adverse events · adults with Major Depressive Disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Remission · adults with Major Depressive Disorder
It is very uncertain whether ketamine changes efficacy: number of participants who achieve remission ‐ at 24 hours… compared with placebo (very low certainty).
1 finding from 1 review
OR 5.6 [1.07, 29.46]
Studies not reported
Very low
Depressive symptoms · adults with Major Depressive Disorder
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Acceptability ‐ total dropouts · adults with Major Depressive Disorder
It is very uncertain whether ketamine changes acceptability: total dropouts№ of participants: 201(6 RCTs) compared with placebo (very low certainty).
1 finding from 1 review
OR 1.25 [0.19, 8.28]
Studies not reported
Very low
Withdrawals due to adverse events · adults with Major Depressive Disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of oxygen therapy (hours) · patients with the management of transient tachypnea of the newborn
1 finding from 1 review
Need for continuous positive airway pressure (yes/no) · patients with the management of transient tachypnea of the newborn
It is very uncertain whether salbutamol changes need for continuous positive airway pressure (yes/no) compared with placebo/no treatment (very low certainty).
1 finding from 1 review
Need for mechanical ventilation · patients with the management of transient tachypnea of the newborn
It is very uncertain whether salbutamol changes need for mechanical ventilation (yes/no) compared with placebo/no treatment (very low certainty).
1 finding from 1 review
Duration of respiratory support (intermittent positive pressure ventilation or continuous positive airway pressure; hours). · patients with the management of transient tachypnea of the newborn
1 finding from 1 review